Matches in Wikidata for { <http://www.wikidata.org/entity/Q37312668> ?p ?o ?g. }
- Q37312668 description "article científic" @default.
- Q37312668 description "article scientifique" @default.
- Q37312668 description "articolo scientifico" @default.
- Q37312668 description "artigo científico" @default.
- Q37312668 description "artículu científicu espublizáu en 2016" @default.
- Q37312668 description "bilimsel makale" @default.
- Q37312668 description "bài báo khoa học" @default.
- Q37312668 description "scientific article published on 28 September 2016" @default.
- Q37312668 description "vedecký článok" @default.
- Q37312668 description "vetenskaplig artikel" @default.
- Q37312668 description "videnskabelig artikel" @default.
- Q37312668 description "vědecký článek" @default.
- Q37312668 description "wetenschappelijk artikel" @default.
- Q37312668 description "wissenschaftlicher Artikel" @default.
- Q37312668 description "наукова стаття, опублікована у вересні 2016" @default.
- Q37312668 description "научни чланак" @default.
- Q37312668 description "مقالة علمية نشرت في 28 سبتمبر 2016" @default.
- Q37312668 name "Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial" @default.
- Q37312668 name "Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial" @default.
- Q37312668 name "Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial." @default.
- Q37312668 type Item @default.
- Q37312668 label "Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial" @default.
- Q37312668 label "Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial" @default.
- Q37312668 label "Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial." @default.
- Q37312668 prefLabel "Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial" @default.
- Q37312668 prefLabel "Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial" @default.
- Q37312668 prefLabel "Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial." @default.
- Q37312668 P1433 Q37312668-31B9C7D0-F68A-4E77-BFCF-F48440F69566 @default.
- Q37312668 P1476 Q37312668-CF41AC5A-C28B-49EE-BDEF-214CA53C5A61 @default.
- Q37312668 P2093 Q37312668-1BE3015A-4BCB-49A5-A140-D146199A22F5 @default.
- Q37312668 P2093 Q37312668-2EACEC7C-0B82-4AE3-A2D1-FE895008658E @default.
- Q37312668 P2093 Q37312668-5B14E17B-5461-41B7-8745-222743598956 @default.
- Q37312668 P2093 Q37312668-8935C0B9-C166-4F3B-9C39-20E0280DEFE6 @default.
- Q37312668 P2093 Q37312668-A76334C3-B8AD-44A3-B31D-DEB2EA8690D4 @default.
- Q37312668 P2093 Q37312668-AF3238AD-B8A1-4F34-84DF-F91B7283FC1E @default.
- Q37312668 P2093 Q37312668-F6219686-5C7A-4956-B117-63F998335569 @default.
- Q37312668 P2093 Q37312668-FA2A087D-5EBA-4492-B30F-24D78EFC3464 @default.
- Q37312668 P2093 Q37312668-FFDCEEA1-42DD-44FA-B607-F4EAFF6B08B6 @default.
- Q37312668 P2860 Q37312668-247273AE-32ED-4B5F-B79A-6D48D4457C5E @default.
- Q37312668 P2860 Q37312668-2FB44C6E-0390-42E4-B055-2D3187543A79 @default.
- Q37312668 P2860 Q37312668-4963526B-6F13-4A99-843D-175E0E7257B4 @default.
- Q37312668 P2860 Q37312668-4C7EB92E-5BE0-4346-A77B-0109EB7646A6 @default.
- Q37312668 P2860 Q37312668-50BECFC8-215B-42A1-B670-891355541271 @default.
- Q37312668 P2860 Q37312668-527D2DC7-9C45-4CA3-8AF6-63553ED5BB6D @default.
- Q37312668 P2860 Q37312668-57679D7C-DCB2-47BB-A1FE-342459A471FF @default.
- Q37312668 P2860 Q37312668-58D99B9E-A18B-48B9-B90C-918E1A851064 @default.
- Q37312668 P2860 Q37312668-5CD196B9-4DF3-4E24-936C-EF94B94CD8E1 @default.
- Q37312668 P2860 Q37312668-5D130710-AA96-4924-9276-BEA6959F06EA @default.
- Q37312668 P2860 Q37312668-5D710766-DE83-4C37-AB94-00E5567735B1 @default.
- Q37312668 P2860 Q37312668-63E39E92-684E-44A3-8D74-653FF78DAA0A @default.
- Q37312668 P2860 Q37312668-69C0F24F-63C6-473D-9738-ED7938668A91 @default.
- Q37312668 P2860 Q37312668-76EE1B26-4B3A-4D0C-9764-A53FF90B2E79 @default.
- Q37312668 P2860 Q37312668-78613E25-210E-4030-8BBC-8F4CAE041317 @default.
- Q37312668 P2860 Q37312668-8743293E-C28E-496E-AA16-D317829AE1BB @default.
- Q37312668 P2860 Q37312668-89C1C743-72B9-4CC0-BDE6-1D00066246C4 @default.
- Q37312668 P2860 Q37312668-8F12747A-D5C5-4D09-BBC7-5FA944B520F6 @default.
- Q37312668 P2860 Q37312668-9DC38114-B406-4499-AB5F-9EB55BBC10D6 @default.
- Q37312668 P2860 Q37312668-9DCB3170-B938-44AE-8E1E-E1E50F99FD98 @default.
- Q37312668 P2860 Q37312668-A548C01E-DCE4-4C17-9C06-21136E5F5990 @default.
- Q37312668 P2860 Q37312668-A593A84A-84F7-4C80-A1B8-777519FC57FD @default.
- Q37312668 P2860 Q37312668-A5F73CBC-FB4C-4D11-BCD6-4787937CEDA6 @default.
- Q37312668 P2860 Q37312668-A87FD73E-3841-48AF-8D76-AE7B17A9ADBC @default.
- Q37312668 P2860 Q37312668-AD6E26AB-3618-4872-B5F5-CE8ED1B1FB3D @default.
- Q37312668 P2860 Q37312668-AE03D683-F8E0-4F04-94C4-64709208D42F @default.
- Q37312668 P2860 Q37312668-B3C583C7-C2A9-4E9F-BA34-65E79FFBF548 @default.
- Q37312668 P2860 Q37312668-CB282909-A3CD-4514-BB84-5B16BDF620EF @default.
- Q37312668 P2860 Q37312668-CF0B7864-4C76-489E-83CA-9A9C2DC792EE @default.
- Q37312668 P2860 Q37312668-D1DA085F-0ADF-4A85-86F1-0F723449DDDF @default.
- Q37312668 P2860 Q37312668-D2EC7531-47B0-4484-B9DA-56166FA29C5C @default.
- Q37312668 P2860 Q37312668-D3D5AD94-644D-450C-A639-2B3CE1964FE8 @default.
- Q37312668 P2860 Q37312668-D49BF35C-56AF-466B-A3BA-8E870A3DC000 @default.
- Q37312668 P2860 Q37312668-DC998AFA-C9AD-4BF7-B6AB-68108CD4A1D3 @default.
- Q37312668 P2860 Q37312668-DCED365E-86D6-4DBC-9726-07D6879A468D @default.
- Q37312668 P2860 Q37312668-DDE570B9-05B5-4788-BCB4-C7C64EAC09B8 @default.
- Q37312668 P2860 Q37312668-DF660623-C76E-40EB-B22C-64BE594D3E7B @default.
- Q37312668 P2860 Q37312668-E3D4C356-6D41-40A9-ADA2-D6F8C4995F9D @default.
- Q37312668 P2860 Q37312668-E4C8AAA6-39C4-431C-85A6-F03C36D2833F @default.
- Q37312668 P2860 Q37312668-E64A8168-CD84-45B5-AFEE-9E0FF90F0470 @default.
- Q37312668 P2860 Q37312668-EF8DB797-6FB2-49E8-9678-D10B4C4BE256 @default.
- Q37312668 P2860 Q37312668-F75185DD-0F88-4E8E-A9C2-3B903A0E927C @default.
- Q37312668 P2860 Q37312668-F8528DC7-07C5-4959-8B75-F3CD264EA459 @default.
- Q37312668 P304 Q37312668-7B145015-7531-4DB9-B461-15C86EBB176A @default.
- Q37312668 P31 Q37312668-CA374723-4AFA-466A-B9BC-491673073B37 @default.
- Q37312668 P356 Q37312668-27A0C0B6-F873-4B7A-81A4-A5147B8CF5B8 @default.
- Q37312668 P433 Q37312668-94B9F6DF-CB7C-45F5-8066-A1A7ED34CEE0 @default.
- Q37312668 P478 Q37312668-849A4295-A34A-4A8B-903D-5EABB84C97DB @default.
- Q37312668 P50 Q37312668-B4B60EAF-E65A-4645-8CD0-DB4B86691F8A @default.
- Q37312668 P577 Q37312668-FF519FD2-F207-42AD-8C17-AC7B7D375E6B @default.
- Q37312668 P698 Q37312668-F7C94845-5FE8-4F36-AB17-46FC7DCEE084 @default.
- Q37312668 P921 Q37312668-47757A04-6C95-4942-83BB-FD97097ABDF9 @default.
- Q37312668 P921 Q37312668-AABC0439-6612-4DA8-B277-5E8F5F1F7480 @default.
- Q37312668 P921 Q37312668-B762900F-8360-46B8-A3CF-CD6D02326F74 @default.
- Q37312668 P921 Q37312668-CF1FDD31-C4B6-47EE-8610-4BAB7C3C869E @default.
- Q37312668 P932 Q37312668-29EA59C7-442A-44B0-965C-4FB5CBDB5CF5 @default.
- Q37312668 P356 RMDOPEN-2016-000308 @default.
- Q37312668 P698 27752357 @default.
- Q37312668 P1433 Q27726913 @default.
- Q37312668 P1476 "Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial" @default.
- Q37312668 P2093 "Bethanie Wilkinson" @default.
- Q37312668 P2093 "David Gruben" @default.